Oxford Cancer Biomarkers – An IBM Power AI Vision Use Case
Combining leading-edge diagnostics with AI technology to improve outcomes for cancer patients. Predicting which patients with stage II colorectal cancer will suffer a recurrence after surgery is difficult. However, many are routinely prescribed chemotherapy, even though it may cause severe side effects. In some patients, these can be fatal. Oxford Cancer Biomarkers worked with Meridian IT to apply IBM Power AI Vision to identify novel diagnostic biomarkers in tumour microenvironments, with the potential to enhance early diagnosis and treatment decisions.
